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Abstract: Parathyroid cancers (PCas) are rare malignancies representing approximately 0.005% of all
cancers. PCas are a rare cause of primary hyperparathyroidism, which is the third most common
endocrine disease, mainly related to parathyroid benign tumors. About 90% of PCas are hormonally
active hypersecreting parathormone (PTH); consequently patients present with complications of
severe hypercalcemia. Pre-operative diagnosis is often difficult due to clinical features shared with
benign parathyroid lesions. Surgery provides the current best chance of cure, though persistent
or recurrent disease occurs in about 50% of patients with PCas. Somatic inactivating mutations of
CDC73/HRPT2 gene, encoding parafibromin, are the most frequent genetic anomalies occurring in
PCas. Recently, the aberrant DNA methylation signature and microRNA expression profile have
been identified in PCas, providing evidence that parathyroid malignancies are distinct entities from
parathyroid benign lesions, showing an epigenetic signature resembling some embryonic aspects.
The present paper reviews data about epigenetic alterations in PCas, up to now limited to DNA
methylation, chromatin regulators and microRNA profile.
Keywords: parathyroid cancers; parathormone (PTH); DNA methylation; histones;
methyltransferases; microRNAs
1. Introduction
Tumors of the parathyroid glands frequently occur, showing a prevalence of 0.1%–0.4% in the
general population, increasing up to 4% in postmenopausal women [1]. Parathyroid tumors are often
associated with parathormone (PTH) hypersecretion determining primary hyperparathyroidism
(PHPT), which represents the third most common endocrine disease following diabetes and
thyreopathies. In PHPT, PTH hypersecretion due to tumor parathyroid cell proliferation induces
hypercalcemia by increasing calcium mobilization from bone and calcium reabsorption from kidney.
Most tumors of parathyroid glands are benign lesions, involving one or multiple parathyroid glands.
Parathyroid benign tumor-related morbidity comes from PTH inappropriate and uncontrolled release.
Similarly to other human cancers, parathyroid carcinomas (PCas) display local vascular and tissue
invasiveness, as well as metastatic localization. At variance with the most common human cancers,
PCas are rare, accounting for approximately 0.005% of all cancers. Moreover, precancerous lesions,
potentially evolving in cancer, have not been identified in parathyroid glands. These peculiarities
suggest that parathyroid cells are highly resistant to cancer, though parathyroid cells are stimulated
by several conditions, whose persistence induces cell proliferation: (1) pregnancy increases the rate
of PTH release in the first trimester to face the embryonic needs; (2) chronic calcium and vitamin D
deficiencies induce benign proliferative cell response; (3) congenital inactivating mutations of the
calcium sensing receptor (CASR) gene are associated with parathyroid glands hyperplasia. However,
none of these conditions are associated with PCa development.
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Parathyroid cancers occur both as part of familial syndromes or sporadic cases. PCas can be
diagnosed in 15% of patients affected with hyperparathyroidism-jaw tumor (HPT-JT) syndrome
(Online Mendelian Inheritance in Man-OMIM#145001), harboring inactivating mutations of the
HRPT2/CDC73 gene (reviewed in [2]). HPT-JT patients develop PCas or solitary, rarer multiple,
cystic parathyroid adenomas. PCas have been occasionally reported also in patients affected with
multiple endocrine neoplasia type 1 syndrome (OMIM#131100), harboring inactivating mutations of the
MEN1 gene. MEN1 patients usually develop parathyroid benign hyperplasia [2]. Somatic inactivating
mutations of the HRPT2/CDC73 and MEN1 genes occur also in sporadic PCa cases.
Most of the clinical and molecular studies investigated parathyroid tumor series, including both
benign and malignant cases, often revealing a consistent overlap of the clinical, genetic and epigenetic
features between the two entities. Nonetheless, benign and malignant parathyroid lesions differ in
some genetic and epigenetic aspects. Herein, we focused the attention on PCas characterizing their
clinical, genetic and epigenetic signatures.
2. Clinical Features of Parathyroid Cancers
Parathyroid carcinomas are usually hormonally functional, and patients with PCas are referred for
clinical symptoms of hypercalcemia. Parathyroid hormone (PTH) release is often elevated, and severe
hypercalcemia develops. Serum calcium often exceeds 14 mg/dL, and serum PTH is significantly
elevated commonly between three- and 10-times the upper limit of the normal range. Most common
hypercalcemia-related symptoms are quite unspecific: dehydration, hypotension, mental confusion,
muscle weakness, nausea, anorexia, weight loss and constipation.
Preoperative diagnosis of parathyroid carcinoma is difficult unless patients present with metastatic
disease. Fine needle aspiration is not recommended because of the risk of parathyromatosis [3].
The main challenge in histologic diagnosis consists of distinguishing atypical parathyroid adenomas
from PCas. The two entities have different clinical behaviors reflected in the overall recurrence rates,
disease-free survival and overall survival. Atypical parathyroid adenomas present with a less severe
biochemical profile and demonstrate an indolent clinical course compared with PCas [4].
Treatment options include surgery, while postoperative radiotherapy remains controversial [3].
Indeed, PCas are usually radioresistant; thus, a protocol of radiotherapy has not been established [5].
Moreover, the standard chemotherapy regimen is not available, as chemotherapy is generally
ineffective in the treatment of PCa [5]. Hypercalcemia-related symptoms can be controlled by cinacalcet
HCl, a potent agonist of the calcium sensing receptor (CASR). Activation of CASR on parathyroid cells
by cinacalcet inhibits PTH release [6]. Alternative medical approaches aimed to reduce hypercalcemia
are bone antiresorptive agents, namely bisphosphonates and denosumab [7].
Survival analysis of PCa patients extrapolated from various cancer databases, such as Surveillance,
Epidemiology, and End Results Program (SEER), National cancer Database (NCDB) and the Swedish
Cancer Registry, and from longitudinal retrospective studies at single institutions showed an overall
survival of 85% and 49%–77% after a follow-up of five and 10 years, respectively. Thus, the prognosis
displays a better survival rate than most solid tumors. The recurrence rate is increased in those
patients who manifest lymph node and/or distant metastases, while tumor size is not a prognostic
factor; the mean-time of recurrence ranges between 2.5 and 4.8 years after the initial surgical
intervention. Recurrences are mainly locoregional, and distant metastases occur in one fourth of
patients. Common sites of metastases include lung, bone and liver.
Mortality is usually secondary to intractable hypercalcemia, which leads to progressive end-organ
damage, such as renal failure. The natural progression of PCa is usually that of a slow-growing
neoplasm with a long clinical course complicated by tumor recurrence, reoperations and progressive
end-organ damage due to disturbed calcium homeostasis.
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3. Genetic Features of Parathyroid Cancers
The genetics of PCas is characterized by loss of tumor suppressors, as suggested by frequent loss
of DNA detected by comparative genomic hybridization (CGH) in about 40 PCas [8,9]. In these studies,
the most frequently-detected imbalances were losses of chromosomes 1p, 13q and 17; in particular,
commonly-occurring DNA losses were 1p21-p22 (41%), 13q14-q31 (41%), 9p21-pter (28%), 6q22-q24
(24%), 4q24 (21%) and 17 (30%), whereas gains preferentially involved 19p (45%), Xc-q13 (28%),
9q33-qter (24%), 1q31-q32 (21%), 5 (30%) and 16p (21%).
Whole-exome sequencing in seven PCas showed that PCas had an average of 51 somatic
variants/tumor (range of 3–176) with approximately 58% of variants occurring as nonsynonymous
single nucleotide variants [10]. Loss of the tumor suppressor HRPT2/CDC73, located at 1q31 and
encoding for parafibromin, has been identified in HPT-JT-related PCas and in 70% of sporadic PCas [11],
representing the most common genetic aberration so far identified in PCas. Mutant CDC73 alleles are
preferentially amplified [10]. Loss of parafibromin expression in PCa specimens occurs in about 50% of
cases, and when associated with CDC73 mutations, it predicts a lower overall survival of 10 years [12].
Moreover, losses of adjunctive tumor suppressors have been detected in PCas: inactivating mutations
of PRUNE2 [10] and MEN1 [13] have been found in 18% and 13% of PCas, respectively. PRUNE2 is
located on chromosome 9q21.2 and encodes for a protein with several functions, including suppression
of Ras homolog family member A (RHOA) activity, which results in reduced stress fiber formation
and suppression of oncogenic cellular transformation. The tumor suppressor MEN1 gene, located on
chromosome 11q13 and encoding for menin, is lost in tumors of MEN1 syndrome and in about 30%
of sporadic parathyroid adenomas. At variance with the most common human cancers, inactivating
mutations of RB1 or P53 have not been identified in PCas [14–16].
4. DNA Methylation in Parathyroid Cancers
National and international mapping projects, such as those conducted by the U.S. National
Institutes of Health (NIH) Roadmap Epigenomics Mapping Consortium [17], the International Human
Epigenome Consortium [18], the Cancer Genome Atlas Network [19], European initiative to establish
epigenomic maps of blood cells (BLUEPRINT) and the International Cancer Genome Consortium,
have defined the genome-wide distribution of epigenetic markers in many fetal and adult normal
and cancerous tissues. Unfortunately, no data about parathyroid normal or cancer tissues have been
produced from the derived databases. Few studies have investigated epigenetic signature in PCas;
however, available data provide interesting insights into parathyroid tumorigenesis. Here, we report
these data attempting to define the landscape of epigenetic alterations in PCas.
4.1. Global DNA Methylation Pattern in Parathyroid Cancers
Gene silencing by DNA promoter cytosine phosphate guanine (CpG) islands methylation is
the main and most well-studied epigenetic mechanism in humans, and it is intimately involved
in cancer development [20]. DNA methylation is catalyzed by DNA methyltransferases (DNMTs),
while the erasure of DNA methylation is achieved by ten-eleven translocation (TET) methylcytosine
dioxygenases. TET enzymes convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine and
subsequently to formyl or carboxyl cytosine. Then, modified cytosine is excised by thymine-DNA
glycosylase (TDG) and repaired with an unmodified cytosine. The TET2 genes are frequently mutated
in human cancers [21]. Spontaneous hydrolytic deamination of 5mC to thymine induces a high
percentage of point mutations in germ or somatic cells, contributing to the genetic changes.
Comparing the DNA methylome profiles of seven metastatic PCas, whose CDC73 status was
not investigated, and three normal parathyroid glands, 175 differentially-methylated genes were
identified, while comparing the methylome profiles of PCas with those of 14 parathyroid benign
adenomas, 263 genes with distinct methylation levels were detected [22]. Considering the top 100
differentially-methylated CpG islands, PCas showed the hypermethylation of all examined CpG
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islands with a pattern clearly distinguishable from that detected in normal parathyroid glands,
which displayed low levels of CpG methylation. However, global hypermethylation were not detected
in three PCas harboring CDC73 mutations analyzed using long interspersed nucleotide element-1
(LINE-1), a surrogate marker of genome-wide methylation changes [23]. Indeed, LINE-1 has been
considered more sensitive in detecting decreases in DNA methylation rather than increases [24].
The authors admitted that the discrepancy could be explained by the different position of the analyzed
CpG dinucleotides, the tumor heterogeneity, as well as the cut-offs and algorithms used for the
detection of differential methylation used in both methods.
In line with the global hypermethylation detected by Starker and collaborators, a recent study
reports a consistent reduction of the global 5-hydroxymethylcytosine (5hmC) levels in the analyzed
PCas compared to parathyroid normal glands [25]. All 17 PCas stained negatively for 5hmC, as well as
for TET1.
4.2. Regional DNA Methylation
Quantification of the methylation density by the pyrosequencing technique at the promoter of
several candidate genes in CDC73-mutated PCas [23] showed that APC, SFRP1 and RASSF1A were
hypermethylated, while CTNNB1/β-catenin was not affected. These findings confirmed previously
reported hypermethylation of the APC gene promoter associated with reduced APC mRNA and
protein expression levels and with increased levels of active unphosphorylated β-catenin in five
PCas [22,26]. Other genes regulating the Wnt/β-catenin pathway have been found hypermethylated
in PCas: SFRP1 [22,23], a potent antagonist of the Wnt signaling pathway, SFRP4 and SFRP2 [22].
It is worth noting that SFRP1 silencing by methylation can constitutively activate the Wnt signaling
pathway. Furthermore, rat sarcoma (RAS) association family domain 1 (RASSF1A) is an important
tumor suppressor gene involved in the regulation of cell growth and proliferation, as well as DNA
repair and hypermethylation were frequently reported in many human cancers [27]. Hypermethylated
genes in PCas included also [22]: (1) tumor suppressor genes involved in the cell cycle control,
such as CDKN2B/p15INK4b, CDKN2A/p16INK4; (2) genes involved in apoptosis, such as PYCARD,
SOCS3; (3) phosphatases, such as DUSP8 and PTPN20; (4) transcription factors, including HOXC11,
WT1, GATA4 and HIC1 [28]. In particular, HIC1 encodes a transcriptional repressor shown to
participate in complex regulatory loops resulting in increased p53 activation and inhibition of E2
transcription factor 1 (E2F1) through direct and indirect interactions with sirtuin 1 (SIRT1). In PCas,
hypermethylation of HIC1 is associated with reduced gene expression, due to repressive histone
H3K27me2/3 modifications induced by the polycomb repressor complex 2 (PRC2) member Enhancer
of Zeste Homolog 2 (EZH2) [28].
No MEN1 or CDC73 promoter hypermethylation could be detected in PCas [23,29,30], despite a
previous study reporting methylation of the CDC73 gene promoter in two out of 11 PCa samples [31].
These findings suggest that the mutational status of these two genes is unlikely to direct the tumors
toward a different methylation profile. Similarly, no alteration of the CpGs methylation has been
detected in the promoter region of the calcium sensing receptor (CASR) and vitamin D receptor (VDR)
genes, two key molecules of parathyroid cells, conferring the sensitivity to extracellular calcium and
precociously downregulated in parathyroid tumors [32,33].
A minority of aberrant methylated genes in PCas compared with normal parathyroid glands
displayed hypomethylation [22]. In particular, hypomethylation of the promoter region of the
microRNAs cluster on chromosome 19 (C19MC) has been detected in more than a half of PCas,
though it did not correlate with C19MC microRNA expression levels [34].
The available data, summarized in Table 1, highlighted a specific “methylome” in PCas:
(1) PCas are characterized by hypermethylation rather than reduced levels of methylation,
consistent with the loss of tumor suppressor genes as a hallmark of parathyroid tumorigenesis;
(2) All of the hypermethylated genes in PCas are hypermethylated also in benign parathyroid tumors;
indeed, in PCas, the hypermethylation levels are more consistent;
Int. J. Mol. Sci. 2017, 18, 310 5 of 13
(3) PCas show hypermethylation of the promoter region of genes commonly hypermethylated in
human cancers, namely CDKN2B/p15, CDKN2A/p16, SFRPs, RASSF1, HIC1 and APC [35];
(4) The promoter regions of the tumor suppressor genes known to be involved in parathyroid
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by increased methylation;
therefore, methylation is not the major molecular mechanism inducing their loss in parathyroid
tumor cells;
(5) Hypermethylation affects the promoter of genes encoding molecules of the Wnt/β-catenin
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafibromin,
which is a member of the polymerase II complex interacting with β-catenin [36]. Therefore,
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37]
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the
detection of total β-catenin at the nuclear level [38].
Table 1. Aberrant gene expressions and related molecular mechanisms in parathyroid carcinomas
compared with normal parathyroid glands.
Gene ID Chr. Map Gene Function Variationin PCas
Frequency
in PCas
Loss of function mutated genes
CDC73 1q31.2 Tumor suppressor involved in transcriptionaland post-transcriptional control
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70
PRUNE2 9q21.2 Tumor suppressor involved in the suppressionof Ras homolog family member A activity
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MEN1 11q12 Tumor suppressor associated withMEN1 syndrome
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Hypermethylated genes
HIC1 17p13 Tumor suppressor involved in inhibition ofE2F1 through interaction with SIRT1
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2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
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APC 5q22.2 Tumor suppressor, inhibitor of theWnt/β-catenin pathway
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(4) The promoter regions of the tu or uppressor genes known to be involved in parathyroid
tumorigenes s, namely CDC73, MEN1, CASR and VDR, are not affected by increased
methylation; therefore, ethylation is not the maj r mol cular mechanism ind cing their loss
in parathyroid t or cells; 
(5) Hypermethylation aff cts the promote of genes encoding olecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafibromin, 
which is a member of the polymerase II co plex interacting with β-catenin [36]. Therefore, 
W t/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-cat nin at the nuclear level [38]. 
Table 1. Aberrant gene expressions and related mole ula  mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene Function Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.2 
Tumor suppressor involved in transc iptional and 
post-transcriptional control 
 70% 
PRU E2 9q21.2 
r s ress r i l e  i  the suppression of 
Ras homolog family member A activity 
18  
MEN1 11q12 
r s ress r associated with  
MEN1 syndrome 
 13  
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
through interaction with SIRT1 
  
APC 5 2 2
Tumor suppressor, inhibitor of the  
W t/ - t i  t w  
33%–100% 
RASSF1A 3p21.31 Ras-association domai  family 1  100% 
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
nt/β-cate in p th ay  100% 
SFRP2 4q31.3 
Secreted frizzle  related protein 2, inhibitor of the 
nt/β-catenin path ay  n.a. 
FRP4 7 14 1
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-catenin pathway 
CDKN2A/p16 9p21.3 Cyclin-dependent kinase inhibitor  n.a. 
CDKN2B/p15 9p21 3 Cyclin-dependent kinase inhibitor  n.a. 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Replication-dependent histone 1.2  100% 
HIST1H2AB 6p22.2 Replication-dependent histone H2A  n.a. 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
33%–100%
RASSF1A 3p21.31 Ras-association domain family 1
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(4) The promoter regions f the tumor suppress r genes know  to be involved in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by increased 
methylation; therefore, methylation is not the major molecular mechanism inducing their loss 
in parathyroid tumor cells; 
(5) Hypermethylation affects the promoter of genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafibromin, 
which is a member of the polymerase II complex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorig nesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutiv  accumulation of active u pho ph ryl ted β-c tenin [26] and others fa ling in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberrant gene expressions and related molecular mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene Function Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.  
Tumor suppressor involved in transcriptional and 
p st-transcriptio al contr l
 70% 
PRUNE2 9q21.2 
Tumor suppressor involved in the suppression of 
Ras homol g family member A activity 
 18  
MEN 1q  
T mor suppressor associated with  
MEN1 syndrome 
13  
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
through interaction with SIRT1 
 100% 
APC 5q22.2 
Tumor su pressor, i hibitor of the  
nt/β-cate in p th ay  33%–100% 
RASSF1A 3 21.31 Ras-association dom in family 1  100  
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
Wnt/β-catenin pathway  100% 
SFRP2 4q31.3 
Secreted frizzled related protein 2, inhibitor of the 
W t/β-catenin pathway  n.a. 
SFRP4 7 14.1 
Secreted frizzled related protein 4, i hibitor of the 
Wnt/β-cat in pathway  n.a. 
CDKN2A/p16 9 1 3 Cyclin-depend t ki ase inhibitor 
CDKN2B/p15 p21.3 Cyclin-d pendent kinas  inhibitor  n.a. 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expres ed chromatin remodeling ge es
HIST1H1C 6p22.2 Re lication-dependent histone H1.2  100% 
HIST1H2AB 6p22.2 Replication-dependent histone H2A  n.a.
HIST1 2BB 6p22.2 Replication-dependent histone H2B  n.a.
EZH2 7q36.1 
Enhancer of zeste 2 p ycomb repressive complex 
2 subu it 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
10
SFRP1 8p11.21 Secreted frizzled related protein 1, inhibitor ofthe Wnt/β-cateni pathway
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4 The pr moter regions of the tumor suppressor genes known to be inv lved in parathyro d 
tumorigenesis, namely CDC73, MEN1, CASR a d VDR, are not affected by inc eased 
ethylation; therefore, m thylation i  not the major mole ular mechanism inducing t eir loss 
in parathyro d tumor cells; 
(5) Hype methylation ffects the pr moter of genes encoding molecules of the Wnt/β-catenin 
p thway (Figure 1). Wnt/β-catenin is po ntially deregulated in PCas by l ss of p rafibromin, 
which s a memb r of the p lymera e II complex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation ha  been ugg sted as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberrant gene expre sions and related molecular mechanisms in p athyro d carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene Fu ction Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.2 
Tumor suppressor invo ved in transcriptional and 
post-tra scriptional con rol 
 70% 
PRUNE2 9q21.2 
Tumor suppressor involved in the suppression of 
Ras homolog family member A activity 
 18% 
MEN1 11q12 
Tumor suppressor associated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
through interaction with SIRT1 
 100% 
APC 5q 2.2 
Tumor suppressor, inhibitor of the  
Wnt/β-catenin pathway  33%–100% 
RASSF1A 3 21.31 Ras-association domain family 1  100  
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
Wnt/β-catenin pathway  100  
SFRP2 4 3
Secreted frizzled related protein 2, inhibitor of the 
Wnt/β-catenin pathway 
SFRP4 7 14 1
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-catenin pathway n.a. 
CDKN2A/p16 9p21.3 C clin-depe dent kinase inhibitor  n.a.
CDKN2B/p15 9p21.3 Cycli -dependent kinase inhibitor  n.a. 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypo ethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Replication-dependent histone H1.2  100% 
HIST1H2AB 6p22.2 Replication-dependent histone H2A  n.a. 
HIST1 2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
10
SFRP2 4q31.3 Secreted frizzled related protein 2, inhibitor ofthe Wnt/β-cateni path ay
Int. J. Mol. Sci. 2016, 18, 310 5 of 12
 
4 he pr moter re ions of the tumor suppress r genes known to be inv lve  in parathyro d 
tu origenesis, namely CDC73, MEN1, CASR and VDR, are not affected by inc eased 
methylation; therefore, m thylation i  not the major mole ular mechanism inducing t eir loss 
in parathyro d tumor cells; 
(5) Hype methylation ffects the pr moter of genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by l ss of p rafibromin, 
which s a member of the polymerase II co plex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been sugg sted as a “hub” f parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutiv  accumulation of active unphosph rylated β-c tenin [26] and others fa ling in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberrant gene expressions and related molecular mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene Function Variation in 
PCas 
Frequency in 
PCas
Loss of function mutated genes 
CDC73 1q31.2 
Tu or suppressor invo ved in transcriptional and 
post-t a scripti nal con rol 
 70  
PRU E2 9q21.2 
Tumor suppressor involved in the suppression of 
Ras homolog f mily member A act vity 
 18  
MEN1 1q 2 
T mor suppressor associated with  
MEN1 syndrome 
 13  
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
through interaction with SIRT1 
 100% 
APC 5q 2.2 
Tumor suppressor, inhibitor of the  
t/β-catenin path ay  33%–100% 
RASSF1A 3p21.31 Ras- ss ciation domain family  
SFRP1 8p11.21 
Secreted frizzled related protein 1, i hibitor of the 
nt/β-cat in path ay  100  
SFRP  4
Secreted friz led related protein 2, inhibitor of the
nt/β-catenin path ay 
SFRP4 7p14.1
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-catenin pathway  n.a. 
CDKN2A/p16 9p21.3 C clin-depe dent kinase inhibitor  n.a.
CDKN2B/p15 9p21.3 Cycli -dependent kinase inhibitor  n.a. 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypo ethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Re lication-dependent histone 1.2  100% 
HIST1H2AB 6p22.2 Replication-dependent histone H2A  n.a.
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a.
EZH2 7q36.1 
Enhancer of zeste 2 p ycomb repressive complex 
2 subu it 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
SFRP4 7p14.1 Secreted frizzled relate protein 4, inhibitor ofthe Wnt/β-cateni pathway
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(4) he pr moter re ions of the tumor suppress r genes known to be involve  in parathyroid 
tu origenesis, namely CDC73, MEN1, CASR and VDR, are not ffected by increased 
methylation; therefore, methylation is not the major molecular mechanism inducing their loss 
in parathyroid tumor cells; 
(5) Hypermethylation affects the promoter of genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafibromin, 
which s a member of the polymerase II co pl x inter ting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been sugg sted as  “hub” f parathyroid tumorig nesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberr nt gene expressions and related molecular mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene Function Variation in 
PCas 
Frequency in 
PCas
Loss of function mutated genes 
CDC73 1q31.2 
Tu or suppressor invo ved in transcriptional and 
p st-t a scripti al con r l 
 70% 
PRU E2 9q2 .2 
  i l  i  the suppression of 
Ras homol g f mily member A act vity 
 18  
MEN  11q1  
 p  associated with  
MEN1 syndrome 
 13  
ypermethylated genes
HIC1 17p1  
Tumor suppressor involved in inh bit on of E2F1 
through interact on with SIRT1 
APC 5 22 2
Tumor suppressor, inhibitor of the  
33%–100% 
RASSF1A 3p21.31 Ras- ss ciation domai  family  
SFRP1 8p11.21 
Secreted frizzled related protein 1, i hibitor of the 
Wnt/β-cat in p thway  100% 
SFRP  4
Secreted friz le  related protein 2, inhibitor of the
t/β-catenin path ay . . 
SFRP4 7p14.1 
Secreted frizzled related protein 4, i hibitor of the 
Wnt/β-cat in pathway  . .
CDKN2A/p16 9 1 3 C clin-depe d t ki ase inhibitor 
CDKN2B/p15 9 1.3 Cycli -d pend t kinas  inhibitor  n.a. 
WT1 11p13 Wilms tumor 1, tumor suppr ssor  . . 
Hypo ethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Re lication-dependent histone 1.2   
HIST1H2AB 6p22.2 Replication-dependent histone H2A  n.a.
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
CDKN2A/p16 9p21.3 Cycli -depende t kinase inhibitor
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(4) The promoter egions of the tumor suppressor genes known to be involved in parathyroid 
tumo igenesis, namely CDC73, MEN1, CASR a d VDR, are not affected by increased 
methylation; therefore, methylation is not the major molecular mechanism inducing their loss 
in parathyroid tumor cells; 
(5) Hypermethylation affects the promoter of g nes encodi g molecules of the Wnt/β-catenin 
p thway (Figure 1). Wnt/β-catenin is po ntially deregulated in PCas by loss of parafibromin, 
which is a member of the p lymera e II co plex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutiv  accumulation of active unphosph rylated β-c tenin [26] and others fa ling in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberrant gene expre sions and related molecular echanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr  
Map 
Ge e Fu ction Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.2 
Tumor suppressor involved in transcriptional and 
post-transcriptional control 
 70% 
PRUNE2 9q2 .2 
  i l  i  the suppression of 
Ras homolog family member A activity 
 18  
MEN1 1q  
  associated with  
MEN1 syndrome 
 13  
Hypermethylated genes
HIC  7  
Tumor suppressor i volved in inh bit on of E2F1 
through int ract o  with SIRT1 
APC 5 2 2
Tumor suppressor, i hibit r of the  
33%–100% 
RASSF1A 3 21.31 Ras-associati n do ai  family 1  100  
FRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
Wnt/β-cate in p thway 100  
SFRP2 4 31.3 
Secreted frizzl  related protein 2, inhibitor of th  
Wnt/β-catenin pathway  n.a. 
FRP4 7 14.1 
Secreted frizzl d related protein 4, inhibitor of th  
Wnt/β-c tenin pathway  . . 
CDKN2A/p16 9p21.3 Cyclin-dependent kinase inhibitor  n.a. 
CDKN2B/p15 1.3 Cyclin-depende t kinase inhibitor  n.a. 
WT1 11p13 Wilms tumor 1, tumor suppressor  . . 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Re lication-dependent histone H1.2  100% 
HIST1H2AB 6p22.2 Replication-dependent histone H2A  n.a.
HIST1 2BB 6p22.2 Replication-dependent histone H2B  n.a.
EZH2 7q36.1 
Enhancer of zeste 2 p ycomb repressive complex 
2 subu it 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
CDK 2B/p15 9p21.3 Cyclin-dep ndent ki ase inhibitor
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(4) The promoter regi ns of the tumor suppressor genes known to be involve  in parathyr id
tumo igenes s, namely CDC73, MEN1, CASR and VDR, are not affected by increased 
methylation; therefore, met ylati n is not the major m lecular m h nism induci g th ir loss
in parathyroid tumor cells; 
(5) Hypermethylation aff cts the pr oter of gen s e coding olecules of the Wnt/β-catenin
pathway (Figure 1). Wnt/β-catenin is otentially deregulated in PCas by l ss of pa afibromi ,
which is a member of the polymerase II complex interac ing with β-catenin [36]. Therefore,
W t/β-catenin deregulation h s been suggested as a “hub” of parathyroid umorige esis [37]
(Figure 1). Indeed, accumulation of β-cat nin is controversial in PCas, with studies reporting 
constitutive accu ulation of active unphosphorylated β-catenin [26] and thers failing in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberrant gene expressions and related molecular mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene Functio  Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.  
Tu or sup res or involved in tr scriptional and 
post-transcrip io al co trol 
 70  
PRUNE2 9q21.2 
Tumor uppressor i volved in the suppression of 
Ra  ho olog family ember A activity 
18  
MEN1 11q 2 
Tum r suppr s or associated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p  
Tumor suppre sor involved in nhib tion of E2F1 
thr ugh int ractio  with SIRT1 
 100% 
APC 5q 2.2 
Tumor suppressor, i hibit r of the  
nt/β-catenin p thway  33%–100% 
RASSF1A 3p21.31 Ras-association dom i  family 1  100% 
1 8p11.21 
    1,    
  
 100% 
SFRP2 4q31.3 
Secreted frizzle  related protein 2, inhibitor of the 
Wnt/β-cate in p thway  n.a. 
FRP4 7 14 1
Secreted frizzled related prot in 4, inhibitor of the 
Wnt/β-cate in p thway 
A/ 6 2  li - nt i  i i it  . . 
CDKN2B/p15 9 2 Cyclin-dependent kina e inhibit  n.a. 
WT1 11p13 Wi ms tumor 1, tu or suppr ssor  n.a. 
ypomethylated genes
C19MC 19q13 42 mi roRNA cluster 58% 
Aberrantly exp ssed chromatin remodeling genes
HIST1H1C .  li ti -  i t  .2  100% 
I H A  .  li ti - t i t  A  . . 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enh ncer of zeste 2 p lycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway reg lator; PRUNE2, prune ho olog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
WT1 11p13 Wilms tumor 1, tumor suppressor
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(4) The promoter regions of the tu or suppressor genes known to be involved in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by increased 
methylation; therefore, ethylation is not the maj r mol cular mechanism ind cing their loss 
in parathyroid t or cells; 
(5) Hypermethylation aff cts the pr moter of genes encod g molecules of the Wnt/β-cateni  
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafibromin, 
which is  member of the polymerase II complex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulati n has been suggested as a “hub” of parathyroid tumorig nesis [37] 
(Figure 1). Indeed, accumulation of β-cateni  is controversial in PCas, with studies reporting 
constitutiv  accumulation of active unph sph rylated β-c tenin [26] and others fa ling in the 
detection of total β-cat nin at the nuclear level [38]. 
Table 1. Aberrant gene expressions and related mole ula  mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Ge e Function Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q3 .2 
Tumor sup ressor i volved in tra scriptional and 
st-transcrip io al co tr l 
 70% 
PRU E2 9q2 .2 
  i l  i  the suppression of 
Ras homol g family member A activity 
 18  
MEN  1q  
  associated with  
MEN1 syndrome 
 13  
Hypermethylated genes
HIC1 17p13 
Tumor suppressor i volved in nh bit on of E2F1 
thr ugh int ract o  with SIRT1 

APC 5 2.2 
Tumor uppressor, i hibit r of the   33%–100% 
RASSF1A 3p21.31 Ras-associati n do ai  family 1  100% 
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
nt/β-cate in p th ay 100  
SFRP2 4q31.3 
Secreted frizzl  related protein 2, inhibitor of th  
t/β-catenin path ay  n.a. 
FRP4 7 14.1 
Secreted frizzl d related protein 4, i hibitor of th  
Wnt/β-c t in pathway  . . 
A/ 6 1 3 li - t i s  i i itor  
CDKN2B/p15 9 .  Cycli -d pend t kina  inhibit   . .
WT1 11p 3 Wilms tumor 1, tumor uppr ssor  . . 
Hypo ethylated gen s 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Replication-dependent histone 1.2  100% 
I A  .  li ti - t i t  A  . . 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a.
EZH2 7q36.1 
Enhancer of zeste 2 p ycomb repressive complex 
2 subu it 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune ho olog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
Hypomethylated genes
C19MC 19q13.42 microRNA cluster
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(4) The promoter regions of the tumor suppressor genes known to be involved in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by increased
methylation; therefore, methylation is not the major molecular mechanism inducing their loss 
in parathyroid tumor cells; 
(5) Hypermethylati    ter f enes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). t/β-catenin is potentially der gulated in PCas by loss of parafibromin, 
which is a member of the poly erase II co plex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37]
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutive accumulati n of active unphosph rylated β-cate in [26] and others failing in the 
detecti n of total β-catenin at the nuclear level [38]. 
Table 1. Aberrant gene expressions and related m lecular mech nisms in parathyroid carc nomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene Function Variation in 
PCas 
Fr quency in 
PCas 
Loss of funct on mutated genes 
CDC73 1q31.2 
Tumor suppressor involved in transcriptio al and 
post-tra scriptional control 
 70% 
PRUNE2 9q21.2 
Tumor suppressor involved in the suppression of 
Ras homolog family member A activity 
 18% 
MEN1 11q12 
Tumo  suppress r associated with  
MEN1 syndrome 
 13% 
Hypermethylated en s
HIC1 17p 3 
  i l  i  inhibition of E2F1 
th o gh interaction with SIRT1 
 100  
APC 5q22  
 , i h bitor f the  
Wnt/β-catenin pat way  33%–100% 
RASSF1A 3p21.31 Ras-ass ciation domain family 1  100% 
SFRP 8 11. 1 
Secreted frizzl d related protein 1, nh bitor of the 
nt/β-caten n path ay 100
SFRP2 4 31 3
Secreted frizzled related protein 2, inhibitor of the 
n.a. 
SFRP4 7p14.1 
Secreted frizzled related protei  4, inhibitor of the 
Wnt/β-catenin pathway  n. . 
CDKN2A/p16 9 2 3 Cyclin-dep nde t kin se inhibitor .a. 
CDKN2B/p15 9p2 .3 Cyclin- e ndent ki se inhibitor  n.a. 
WT  1  Wilms tumor 1, tumor suppressor n.a. 
Hypomethylated genes 
C19MC 19 3 42 microRNA cluster  58
Aberrantly expressed chromatin remodeli g ge es
HIST1H1C 6 2.2 Replication-dep de t histo e H1.2  100% 
HI T1H2AB 6p22.2 Replication-dep de t hist n  H2A . . 
HIST1H2BB 6 2 2 Replication-dep de t histone H2B 
EZ 2 7q36.1 
Enhancer of zest  2 p lyco b repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parath roid carci omas; CDC73, cell division cycle 73; APC, Wnt signaling
pathway regulator; PRUNE2, pru  hom og 2; MEN1, multiple ndocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in hum n ca c rs ; SIRT1, sirtuin 1; C19MC, chromosome 19 
icroRNA cluster; n.a., not available. 
58%
Aberrantly expressed chromatin remod ling g nes
HIST1H1C 6p22.2 Replica ion-d pe dent istone H1.2
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(4) The promoter regi s of the tu or suppressor genes k own to be involve  in parathyr id
tumo igenes s, namely CDC73, MEN1, CASR and VDR, are not affected by increase  
methylation; therefore, met ylation is not the major m lecular m hanism in uci g heir loss
in parathyroid tum r cells; 
(5) Hypermethylation affects the promoter of gen s e coding molecules of the Wnt/β-catenin
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafibromin,
which is a member of the polymerase II complex interacting with β-catenin [36]. Therefore,
W t/β-catenin deregulation h s been suggested as a “hub” of parathyroid umorige esis [37]
(Figu e 1). Indeed, accumulation of β-cat nin is co troversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-cateni  [26] and others faili g in the 
detection f total β-cat nin at the nuclear level [38]. 
T ble 1. Aberrant gen  expressions and relat d molecular mechanisms in parathyroid carcinomas 
compared with ormal parathyr id glands. 
Gene ID Chr. 
Map
Ge e Function V riati  in 
PCas 
Frequency i  
PCas 
Loss of function mutat  genes 
CDC73 1q31.2 
Tu or suppressor involved in trans ripti nal and 
ost-transcriptional co trol 
 70%
PRUNE2 9q21.2 
Tumor up ressor involved in the suppression of 
Ra  omolog family member A activity 
 18% 
MEN1 11q12 
Tumor suppressor associated with  
MEN1 y dr me 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
through interaction with SIRT1 
 100% 
APC 5 22
Tum r uppr ssor, i hibitor of the  
Wnt/β-catenin p thway 33%–100% 
RASSF1A 3p21.31 Ras-association dom in family 1  100  
SFRP1 8p11.21 
Secreted frizzled rel ted protei  1, inhib tor of the 
nt/β-catenin pathway  100% 
SFRP2 4 3
Secreted frizzled lated protein 2, inhibit r of the
nt/β-catenin p thway n.a. 
SFRP4 7p14 1
Secreted frizzl d related protein 4, nh bitor of the
Wnt/β-caten n pathway n.a. 
2A/p16 9p2 .  yclin- e ende t kin se inhibi or  n.a. 
B 5
WT1 11p  Wil s tumor 1, tu or uppress
Hypomethylated gen s 
C19MC 19 13.42 m croRNA clus er  58  
Aberrantly expressed chromatin remode ing gen
HIST1H1C 6p22.2 eplication-dep dent histone 1.2  100% 
IST1 2 B 2A n.a. 
B   B
EZH2 7q36.1 
Enh ncer of zest  2 p lyco b r pressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell div sion cycle 73; APC, Wnt signaling 
pathway reg lator; PRUNE2, pru  hom log 2; MEN1, multiple ndocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in u n canc rs 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
100
HIST1H2AB 6p22.2 Replica ion-d pe d n hist ne H2A
m 
N
W w

H
n.a.
HIST H2BB 6p22.2 Replication- pendent histone H2B
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(4) The promoter regions of the tumor suppressor genes known to be involved in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by increase  
methylation; therefore, methylation is not the major molecular mechanism in ucing their loss 
in parathyroid tumor cells; 
(5) Hypermethylation affects the promoter of genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafibromin, 
which is a member of the polymerase II complex interacting with β-catenin [36]. Theref re, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutive ccu ulation of active unphosph rylated β- ate in [26] and others failing in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberrant gen  expressions and related molecular mechanis s in p athyro d carcinomas 
compared with or al parathyroid glands. 
Gene ID Chr. 
Map
Gene Function Variati n in 
PCas 
Frequ ncy i  
PCas 
Loss of function mutated gen s 
CDC73 q3 .  
Tu or sup res or involved in tr nsc iptio al and 
ost-transc iption l co trol 
70
PRU E2 9q21.2 
Tumor sup ressor involved in the suppression of 
Ra  homolog family member A activity 
 18  
MEN1 1q  
Tum r uppr ssor associ ted wi h  
MEN1 yndrome 
13
Hyp rmethylated genes
HIC1 17p13 
Tu or uppre sor involved in inhib tion of E2F1 
through int raction with SIRT1 
 100  
APC 5q22.2 
Tum r suppr ssor, i hibitor of the  
Wnt/β-catenin pathway  33%–100% 
RASSF1A 3p21.31 Ras-as ociation dom i fam ly 1 100  
1 8p11.2  
1
100  
SFRP2 4q31.3 
Secreted frizzle  related prote  2, inhibitor of the 
t/β-cate i  p th ay  n.a. 
4 7p14.1 
4
n a
n.a. 
2A/p16 2 .  yclin- e en e t kin s  inhibitor n.a. 
B 5
WT1 11p  Wi ms tumor 1, tumor uppr ss
ypomethylated genes
C19MC 1 q13 42 microRNA clus r 58  
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6 22.2 e ication- e en en histon  1.2 100% 
I 1 2A  2A
B   B
EZH2 7q36 1
Enhancer of zeste 2 polyco b repressive complex 
2 subuni
 100% 
Chr., chromosome; PCas, parathyroid car inomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway gulator; PRUNE2, pru e ho log 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in u n canc rs 1; SIRT , sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
EZH2 7q36.1 Enhancer of zeste 2 polycomb repressivecomplex 2 subu it
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(4) The promoter regi ns of the tumor suppressor genes known to be involve  in parathyr id
tumo igenes s, namely CDC73, MEN1, CASR and VDR, are not affected by increased 
methylation; therefore, met ylati n is not the major m lecular m hanism induci g their loss
in parathyroid tumor cells; 
5 Hypermethylation affects the promoter of gen s e coding molecules f the Wnt/β-caten n
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafib omin,
which is a member of th  polymera e II complex intera ting with β-catenin [36]. T erefore,
W t/β-caten n der gulation h s been suggested as  “hub” of parathyroid umorige esi  [37]
(Figu e 1). Indeed, ccumulat on f β-cat nin is co troversial in PCas, with studies reporting
constitutiv  accumulation of active unphosph ryl ted β-c tenin [26] and thers f li g in the
detection f total β-cat nin at the nuclear level [38]. 
able 1. Aberrant en  expressions a d related m lecular mechanisms in parathyroi  carcinomas 
co pared with nor al parathyroid glands. 
Gene ID Chr. 
Map 
Ge e Function V iati  n
PCas 
Frequency in 
PCas 
Loss of function mutat  genes 
CDC73 q3 .  
Tu or suppres or i volved in tr nscriptional and 
post-transcriptional control 
70
PRUNE2 9q21.2 
Tumor suppressor i volved in the suppressi of
Ra  omolog fami y member A activity 
 18% 
MEN1 11q12 
T m r suppr ssor associated with  
MEN1 syndrome 
 13  
Hypermethylated genes
HIC1 17p13 
Tu or suppre sor involved in inhib tion of E2F1 
through i teraction with SIRT1 
 100  
APC 5 22
Tumor uppressor, inhibitor of the  
Wnt/β-catenin p th ay 33%–100% 
RASSF1A 3 21.31 Ras-association dom in family 1  100%
1 8p11.21 
1
100  
SFRP2 4 3
Secreted frizzle  elated pr tein 2, inhibit r of the
nt/β-cate in p thway  . . 
SFRP4 7p14 1
Secreted frizzl d rel ted protein 4, nh b tor of the
nt/β-caten n pathway n.a. 
CDKN2A/p16 p21 3 Cyclin- e endent ki as  inhibi or  n.a. 
CDKN2B/p15 9p2 Cyclin-depende t kin se inhibitor 
WT1 11p1  Wi ms tumor 1, tumor suppr ssor  n.a. 
ypomethylated genes
C19MC 19q13 42 m croRNA cluster 58  
Aberrantly expressed chromatin remode i g gen
HIST1H1C 6p22.2 Replic tion-dep den histo e H .2 
HIST1H2 B 6 22.2 Replic tion-dep dent histo e H2A  .a. 
HIST1 2BB 6 22.2 Replication-dep de t histo e H2B  .a.
EZH  7 6 1
E h ncer of est  2 p yco b r pressive complex
2 subu it 
100% 
Chr., chromosome; PCas, parathyroid car inomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway g lator; PRUNE2, pru e homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT , sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
100
Chr., chromosome; PCas, parathyroid carcinomas; 73, cell division cycle 73; APC, Wnt sign ling
pathway regulator; PRUNE2, prune homolog 2; MEN1, multi l endocrine neoplasia type 1 syndrome; HIC1,
hypermet ylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromos me 19 microRNA cluster; n.a., not available.
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Figure 1. The Wnt/β-catenin pathway is potentially deregulated in PCas. Schematic representation of 
the molecules involved in the Wnt/β-catenin signaling in the inactive (left) and active (right) state: 
molecules, whose expression may be affected by genetic and epigenetic modifications in PCas, are 
indicated. The Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid 
tumorigenesis [37]. DKK1, Dickkopf 1; DVL, disheveled segment polarity protein; SFRP, secreted 
frizzled related protein; CKI, cyclin-dependent kinase inhibitor; GSK3, glycogen synthase kinase 3 β; 
TCF/LEF1, transcription factor 7/lymphoid enhancer binding factor 1; HIC1, hypermethylated in 
cancer 1; WT1, Wilms tumor 1; RASSF1A, Ras-association domain family 1; LRP-5, low density 
lipoprotein (LDL) receptor related protein 5; LRP-6, low density lipoprotein (LDL) receptor related 
protein 6; CDC73, cell division cycle 73; APC, WNT signaling pathway regulator; WNT, 
wingless-type ; ub, ubiquitination; ⊥, inhibitory effect. 
4.3. Chromatin Regulators in Parathyroid Carcinomas 
The genome sequencing efforts of thousands of uncultured tumors have revealed the frequent 
existence of mutations in writers, readers and erasers, thus establishing a causative role for an 
altered epigenome in cancer. Here, aberrant expression of chromatin regulatory molecules identified 
in PCas are reported. 
4.3.1. Histones Modifications in Parathyroid Cancers 
Replication-dependent histones are tightly regulated throughout the cell cycle. Interestingly, 
histone expression is mainly regulated by the processing of the 3′ end of histone transcripts. 
In the absence of parafibromin in CDC73-mutated PCas, replication-dependent histone 
transcripts are not cleaved and contain a poly(A) tail. Loss of parafibromin in HCT116 cells and 
HeLa cells upregulates the replication-dependent histone family; of these, histones H1, H2A, H2B 
and H3 mRNAs are increased. The abnormally polyadenylated histone transcripts display an 
increased mRNA stability. Therefore, parafibromin emerges as a regulator of a posttranscriptional 
pathway critical to cell-cycle progression [39]. In line with these observations, histone H1.2 (histone 
cluster 1 H1 family member c; HIST1H1C (6p22.2)) has been reported up-regulated and highly 
overexpressed in seven sporadic PCas, together with the upregulation of histone H2A (HIST1H2AC 
Figure 1. The Wnt/β-catenin pathway is potentially deregulated in PCas. Schematic representation
of the molecules involved in the Wnt/β-catenin signaling in the inactive (left) and active (right)
state: molecules, whose expression may be affected by genetic and epigenetic modifications
in PCas, are indicated. The Wnt/β-catenin deregulation has been suggested as a “hub”
of parathyroid tumorigenesis [37]. DKK1, Dickkopf 1; DVL, disheveled segment polarity
protein; SFRP, secreted frizzled related protein; CKI, cyclin-dependent kinase inhibitor; GSK3,
glycogen synthase kinase 3 β; TCF/LEF1, transcription factor 7/lymphoid enhancer binding factor 1;
HIC1, hypermethylated in cancer 1; WT1, Wilms tumor 1; RASSF1A, Ras-association domain family 1;
LRP-5, low density lipoprotein (LDL) receptor related protein 5; LRP-6, low density lipoprotein (LDL)
receptor related protein 6; CDC73, cell division cycle 73; APC, WNT signaling pathway regulator; WNT,
wingless-type ; ub, ubiquitination; ⊥, inhibitory effect.
4.3. Chromatin Regulators in Parathyroid Carcinomas
The genome sequencing efforts of thousands of uncultured tumors have revealed the frequent
existence of mutations in writers, readers and erasers, thus establishing a causative role for an altered
epigenome in cancer. Here, aberrant expression of chromatin regulatory molecules identified in PCas
are reported.
4.3.1. Histones Modifications in Parathyroid Cancers
Replication-dependent histones are tightly regulated throughout the cell cycle. Interestingly,
histone expression is mainly regulated by the processing of the 3′ end of histone transcripts.
In the absence of parafibromin in CDC73-mutated PCas, replication-dependent histone transcripts
are not cleaved and contain a poly(A) tail. Loss of parafibromin in HCT116 cells and HeLa cells
upregulates the replication-dependent histone family; of these, histones H1, H2A, H2B and H3 mRNAs
are increased. The abnormally polyadenylated histone transcripts display an increased mRNA stability.
Therefore, parafibromin emerges as a regulator of a posttranscriptional pathway critical to cell-cycle
progression [39]. In line with these observations, histone H1.2 (histone cluster 1 H1 family member c;
HIST1H1C (6p22.2)) has been reported up-regulated and highly overexpressed in seven sporadic PCas,
together with the upregulation of histone H2A (HIST1H2AC (6p22.2)) and histone H2B (HIST1H2BC
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(6p22.2); HIST1H2BD; HIST1H2BK; HIST1H2BO) [40] (Figure 2). These genes belong to the histone
microcluster on chromosome 6p22.2-p21.3.
Moreover, in PCas there is loss of monoubiquitinated H2B at lysine 120 (K120)(H2Bub1).
Parafibromin is required for the maintenance of H2B-K120 monoubiquitination [41] (Figure 2), while the
level of H2B is consistently high in all parathyroid tumors independent of CDC73 expression. H2Bub1
is involved in RNA elongation, while losses of H2Bub1, as well as of nuclear CDC73 expression do not
affect H3K4me3.
4.3.2. Aberrant Expression of Methyltransferases in Parathyroid Cancers
Unmethylated CpG islands are key factors in controlling H3K4me3 levels through recruitment of
H3K4 methyltransferases. CpG islands likewise play an important role in establishing and maintaining
H3K27me3 at bivalent domains. H3K27me3, a pivotal marker in the establishment of repressive
chromatin in both early development and adult organisms, is activated by the polycomb group
(PcG) PCR2. The histone 3 lysine 27 methyltransferase Enhancer of Zeste Homolog 2 (EZH2) is a
member of PCR2. EZH2 mRNA and protein are overexpressed in PCas due to gene amplification [42],
while EZH2 mutations have not been detected in 23 sporadic PCas [43]. EZH2 is involved in H3K27
methylation, and EZH2-mediated epigenetic control of RNA polymerase II (Pol II) transcribed coding
gene transcription has been well established [44,45] (Figure 2). Moreover, the histone methyltransferase
SUV39H1 is potentially deregulated in PCas as its recruitment and induction of H3K9 methylation are
dependent on parafibromin [46] (Figure 2). Unfortunately, SUV39H1 expression and function have not
been investigated so far in PCas.
Considering these limited data, PCas may be supposed to have elevated global H3K27me3 levels.
Indeed, increased EZH2 activity redistributes the H3K27me3 marker across the genome with a complex
effect on transcription, including a loss of H3K27me3 that is associated with increased transcription at
many loci [47].
5. MicroRNAs Deregulated in Parathyroid Cancers
MicroRNAs (miRNAs), single-stranded non coding RNAs of 19–25 nucleotides in length,
are drivers or suppressors of the hallmarks of malignant cells [48]. In general, cancer cells show
a large alteration of miRNA expression compared to their normal counterpart. All tumors show
a specific miRNA signature, referred to as “miRNome”. Each miRNA is predicted to repress the
expression of thousand mRNAs, but, in turn, each mRNA can be targeted by several hundreds of
different miRNAs. Currently, there are about 1800 annotated human miRNA precursor genes that are
processed into more than 2500 mature miRNA sequences (http://www.mirbase.org).
miRNA signature has been investigated in PCas compared with normal parathyroid
glands [34,49,50] and with parathyroid benign tumors [34,50]. These studies identified a global miRNA
downregulation in PCas compared to normal parathyroid glands, reflecting a deregulated pattern
common to human cancers. Nonetheless, the different technical strategies employed produced different
sets of significantly deregulated miRNAs. Among the downregulated miRNAs, miR-296-5p [49],
miR-139-3p [49], miR-126-5p [50], miR-26b [50] and miR-30b [50] were the most significantly varied in
PCas. Few miRNAs were upregulated in PCas; the most significantly varied were miR-222 [49,50],
miR-503 [49] and miR-517c [34,49] (Table 2).
PCa deregulated miRNAs could be detected with a similar pattern of expression in their distant
metastasis: miR-296-5p was downregulated in lung metastasis of a PCa [34], and C19MC miRNAs and
miR-372 were upregulated in samples derived from five PCa metastases [34].
A number of molecular mechanisms may deregulate miRNAs expression in PCas. Loss of
parafibromin, which interacts with RNA polymerase II (Pol II) [51], may potentially alter miRNAs
expression, being a key molecule in miRNA transcription (Figure 2). Unfortunately, the relationship
between loss of parafibromin in PCas and miRNAs expression have not been investigated so far.
The transcriptional repression of miRNAs by hypermethylation of their corresponding promoter loci is
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a common feature of all human tumors [52]. Interestingly, PCas are characterized by the deregulation
of microRNAs belonging to methylated genomic regions, namely the C19MC, miR-371-373 and
GNAS loci.
C19MC cluster: PCas showed miR-519d, miR-518e and miR-517c median expression levels
comparable with those in human placentas, the only human adult tissue physiologically expressing
C19MC miRNAs. Two thirds of PCas showed gains in DNA copies either in the miRNA cluster regions
or at a distant position along chromosome arm 19q, suggesting a genetic mechanism responsible for
the aberrant expression of C19MC miRNAs at least in a subset of PCas [34]. Additionally, the C19MC
promoter was hypomethylated in about half of PCa samples. However, the epigenetic status of the
C19MC promoter was not correlated with miRNAs expression levels [34]. C19MC is the largest human
miRNA gene cluster. It maps on chromosome 19q13.42, spanning about 100 kb and consisting of
46 genes encoding a total of 56 mature miRNAs [53]. miRNAs belonging to the C19MC cluster are
expressed in human embryonic stem cells and rapidly downregulated during the differentiation
process [54]. Expression of C19MC microRNAs increases significantly in trophoblasts from the first
to third trimester of gestation [55], while they are silenced in the majority of adult normal cells by
hypermethylation [56]. C19MC miRNAs are aberrantly expressed in infantile hemangioma [57],
melanotic neuroectodermal tumor of infancy [58], embryonal tumors with multilayered rosettes [59],
testicular germ cell tumors (in particular, in non-seminoma aggressive tumors) [60], glioblastoma [61],
hepatic mesenchymal hamartomas [62], suggesting that C19MC reactivation characterizes tumors with
embryonic features [63].
miR-372: miR-372, which is highly expressed in almost all PCas, belongs to the miR-371-373
cluster on chromosome 19q13.42, which is close to the C19MC cluster. Similarly to C19MC miRNAs,
the miR-371-373 cluster is an “embryonic” cluster. miR-372 is deregulated in many human cancers [64].
miR-296: miR-296-5p is located at the imprinted locus GNAS (guanine nucleotide binding protein
(G protein), α stimulating activity polypeptide 1) on chromosome 20q13. miR-296-5p is expressed from
the paternally-derived allele, arising from the long, noncoding antisense transcript, GNAS antisense
RNA 1 (GNAS-AS1) [65]. It is a tumor suppressor in breast and lung cancers [66,67]. In PCas,
miR-296-5p is downregulated, showing the best predictive value in distinguishing cancers from
normal parathyroid glands [49].
Table 2. Aberrant microRNA expressions in parathyroid carcinomas compared with normal
parathyroid glands.
Gene ID Chr. Map Gene Function Variation in PCas Frequency in PCas
miR-517c 19q13.42 C19MC microRNA cluster
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(4) The promoter regions of the tumor suppressor genes known to be involved in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by increased 
methylation; therefore, methylation is not the major molecular mechanism inducing their loss 
in parathyroid tumor cells; 
(5) Hypermethylation affects the promoter of genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafibromin, 
which is a member of the polymerase II complex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberrant gene expressions and related molecular mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene Function Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.2 
Tumor suppressor involved in transcriptional and 
post-transcriptional control 
 70% 
PRUNE2 9q21.2 
Tumor suppressor involved in the suppression of 
Ras homolog fami y member A act vity 
 18% 
MEN1 11q12 
Tumor suppressor associated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
through interaction with SIRT1 
 100% 
APC 5q22.2 
Tumor suppressor, inhibitor of the  
Wnt/β-catenin pathway  33%–100% 
RASSF1A 3p21.31 R s-association domain family 1  100% 
SFRP1 8p11.21 
Secr ted frizzled related protein 1, i hibit r of the 
Wnt/β-catenin pathway  100% 
SFRP2 4q31.3 
Secreted frizzled related protein 2, inhibitor of the 
Wnt/β-catenin pathway  n.a. 
SFRP4 7p14.1 
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-catenin pathway  n.a. 
CDKN2A/p16 9p21.3 Cyclin-dependent kinase inhibitor  n.a. 
CDKN2B/p15 9p21.3 Cyclin-dependent kinase inhibitor  n.a. 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Replication-dependent histone H1.2  100% 
HIST1H2AB 6p22.2 Replication-dependent histone H2A  n.a. 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
100%
miR-372-3p 19q13.42 miR-371-373 cluster
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(4) The promoter regions of the tumor suppressor genes known to be involved in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by increased 
methylation; therefore, methylation is not the major molecular mechanism inducing their loss 
in parathyroid tumor cells; 
(5) Hypermethylation affects the promoter of genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafibromin, 
which is a member of the polymerase II complex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberra t gene expressions and related molecular mechanisms i  parathyroid carcinomas 
compared with ormal para hyroid glands. 
Gene ID Chr. 
Map 
Gene Function Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.2 
Tumor sup ressor involved in tra scriptional and 
ost-transcriptio al control 
 70% 
PRUNE2 9q21.2 
Tumor uppressor involved in the suppression of 
Ras homolog family member A activity 
 18% 
MEN1 11q12 
Tumor suppres or associated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
thr ugh int ractio  with SIRT1 
 100% 
APC 5q22.2 
Tumor suppressor, inhibitor of the  
Wnt/β-catenin p thway  33%–100% 
RASSF1A 3p21.31 Ras-association domai  family 1  100% 
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
Wnt/β-catenin pathway  100% 
SFRP2 4q31.3 
Secreted frizzled related protein 2, inhibitor of the 
Wnt/β-catenin pathway  n.a. 
SFRP4 7p14.1 
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-cate in p thway  n.a. 
A/ 6 .  li - t i  i i it   . . 
CDKN2B/p15 9p2 .  Cyclin-dependent kina e inhibit   . . 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C .  li ti - t i t  1.2  100% 
I A  .  li ti - t i t  A  . . 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune ho olog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
75%
miR-139-5p 11q
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(4) The promoter regions of the tumor suppressor genes known to be involved in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by increased 
methylation; therefore, methylation is not the major molecular mechanism inducing their loss 
in parathyroid tumor cells; 
(5) Hypermethylation affects the p omote  f genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is po tially deregulated in PCas by loss of parafibromin, 
which is a member of the polymerase II c plex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of tot l β-catenin at the nuclear level [38]. 
Table 1. Aberrant gene expressions and related molecular mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene F nction Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q 1.2 
Tumor suppressor involved in transcriptional and 
post-transcriptional control 
 70% 
PRUNE2 9q21.2 
Tumor suppressor involved in the suppression of 
Ras homolog family member A activity 
 18% 
MEN1 11q12 
Tumor suppressor associated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
throug  interaction with SIRT1 
 100% 
APC 5q22.2 
Tumor suppressor, inhibitor of the  
Wnt/β-catenin pathway  33%–100% 
RASSF1A 3p21.31 Ras-association domain family 1  100% 
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
Wnt/β-catenin pathway  100% 
SFRP2 4q31.3 
Secreted frizzled related protein 2, inhibitor of the 
Wnt/β-catenin pathway  n.a. 
SFRP4 7p14.1 
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-catenin pathway  n.a. 
CDKN2A/p16 9p21.3 Cyclin-dependent kinase inhibitor  n.a. 
CDKN2B/p15 9p21.3 Cyclin-dependent kinase inhibitor  n.a. 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Replication-dependent histone H1.2  100% 
HIST1H2AB 6p22.2 Replication-dependent histone H2A  n.a. 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
miR-296-5p 20q13.32 GNAS imprinted locus
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(4) The prom ter r gions of the tumor suppressor genes known to be involved in parathyroid 
tumorigenesis, na ely CDC73, MEN1, CASR and VDR, are not affected by increased 
methylation; the efore, ethylation is not the major mol cular mechanism inducing their loss 
in parathyroid tumor cells; 
(5) Hypermethylation affects the p omoter f genes encoding molecules of the Wnt/β-cate in 
pathway (Figure 1). Wnt/β-catenin is tially deregulated in PCas by loss of parafibromin, 
whic  is a member of th  polymerase II c pl x i teracting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of p rathyroid tumorigenesis [3 ] 
(Figure 1). Indeed, accumulation of β-cate in is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberrant gene expressions and related molecular mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene Function Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.2 
Tumor sup ressor involved in tra scriptional and 
ost-transcriptional control 
 70% 
PRUNE2 9q21.2 
Tumor uppressor involved in the suppression of 
Ras homolog family member A activity 
 18% 
MEN1 11q12 
Tumor suppres or associated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
thr ug  int ractio  with SIRT1 
 100% 
APC 5q22.2 
Tumor suppressor, inhibitor of the  
Wnt/β-catenin p thway  33%–100% 
RASSF1A 3p21.31 Ras-association domai  family 1  100% 
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
Wnt/β-catenin pathway  100% 
SFRP2 4q31.3 
Secreted frizzled related protein 2, inhibitor of the 
Wnt/β-catenin pathway  n.a. 
SFRP4 7p14.1 
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-cate in p thway  n.a. 
A/ 6 .  li - t i  i i it   . . 
CDKN2B/p15 9p2 .  Cyclin-dependent kina e inhibit   . . 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C .  li ti - t i t  1.2  100% 
I A  .  li ti - t i t  A  . . 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune ho olog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
miR-503 Xq26.3
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(4) The promoter regions of the tumor suppr ssor genes know  to be involv d in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by increased 
methylation; therefore, methylation is not the major olecular mechanism inducing their loss 
in parathyroid tumor cells; 
(5) Hypermethylation affects the promoter of genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by loss of parafibromin, 
which is a member of the polymerase II complex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberr nt gene expressions and related molecular mechanisms in p athyro d carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene Function Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.2 
Tumor suppressor involved in transcriptional and 
post-transcriptional control 
 70% 
PRUNE2 9q21.2 
Tumor suppressor involved in the suppression of 
Ras hom log family me ber A activity 
 18% 
MEN1 11q12 
Tumor suppressor a sociated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
through interaction with SIRT1 
 100  
APC 5q22.2 
Tumor suppressor, inhibitor of the  
Wnt/β-catenin pathway  33%–100% 
RASSF1A 3p21.31 Ras-association domain family 1  100% 
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
Wnt/β-catenin pathway  100% 
SFRP2 4q3 .  
S c eted frizzled related protei  2, i hibitor of the
W t/β-catenin pathw y  . . 
SFRP4 7p14.1 
Sec e ed fr zzled related protein 4, inhibitor of the 
Wnt/β-catenin pathway  .a. 
CDKN2A/p16 9p21.3 Cyclin-dep dent kinase inhibitor  n.a. 
CDKN2B/p15 9p21.3 Cyclin-dependent kinase inhibitor  n.a. 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58  
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Replication-dependent histone H1.2  100  
HIST1H2AB 6p22.  Replication-dependent histone H2A  n.a. 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
miR-222 Xp11.3 miR-221/222 cluster
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4  The promoter regions of the tumor suppressor genes known to be inv lved in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by inc eased 
methylation; therefore, m thylation i  not the major mole ular mechanism inducing t eir loss 
in parathyroid tumor cells; 
(5) Hype methylation ffects the pr moter of genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is potentially deregulated in PCas by l ss of p rafibromin, 
which is a member of the polymerase II complex interacting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of β-catenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberr nt gene expressions and related molecular mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Ge e Function Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.2 
Tumor sup ressor involv d in tra scriptional and 
ost-transcriptional control 
 70% 
PRUNE2 9q21.2 
Tumor uppressor involved in th  suppression f 
Ras hom log family me ber A activity 
 18% 
MEN1 11q12 
Tumor suppres or associated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
thr ugh int ractio  with SIRT1 
 100  
APC 5q22.2 
Tumor suppressor, inhibitor of the  
Wnt/β-catenin p thway  33%–100% 
RASSF1A 3 21.31 Ras-asso iation domai  family 1  100% 
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
W t/β-catenin pathway  100% 
SFRP2 4q3
Secreted frizzled related protein 2, inhibitor of the
Wnt/β-catenin pathway 
SFRP4 7p14.1
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-cate in p thway  .a. 
A/ 6 .  li - t i  i i it   . . 
CDKN2B/p15 9p2 .  Cyclin-dependent kina e inhibit   . . 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58  
Aberrantly expressed chromatin remodeling genes
HIST1H1C .2 li ti - t i t  1.2  100  
I A  .  li ti - t i t  A  . . 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune ho olog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
miR-126-5p 9q34.3
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(4) The promoter regions of the tumor suppressor genes known to be involved in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by increased 
methylation; therefore, methylation is not the major molecular mechanism inducing their loss 
in parathyroid tumor cells; 
(5) Hypermethylation affects the p omote  f genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is po tially deregulated in PCas by loss of parafibromin, 
which is a member of the polymerase II c plex i teracting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulation of atenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-catenin at the nuclear level [38]. 
Table 1. Aberr nt gene expressions and related molecular mechanisms in p athyro d carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Gene F nction Variation in 
PCas 
Frequency in 
PCas
Loss of function mutated genes 
CDC73 1 1.2 
Tumor su press r involved in transcriptional and 
post-transcriptional control 
 70  
PRUNE2 9q21.2 
Tumor suppressor involved in the suppression of 
Ras homolog family member A activity 
 18% 
MEN1 11q 2 
Tumor suppressor associated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
throug  interaction with SIRT1 
 100  
APC 5q22.2 
Tumor suppressor, inhibitor of the  
Wnt/β-catenin pathway  33%–100% 
RASSF1A 3p21.31 Ras-association domain family 1  100% 
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
Wnt/β-catenin pathway  100% 
SFRP2 4q3 .  
Secreted frizzled related protein 2, inhibitor of the 
Wnt/β-catenin pathway  . . 
SFRP4 7p14.1 
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-catenin pathway  .a. 
CDKN2A/p16 9p21.3 Cyclin-dependent kinase inhibitor  n.a. 
CDKN2B/p15 9p21.3 Cyclin-dependent kinase inhibitor  n.a. 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Replication-dependent histone H1.2  100  
HIST1H2AB 6p22.2 Replication-dependent histone H2A  n.a. 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune homolog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
miR-26b 2q35
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4  The promoter regions of the tumor suppressor genes known to be inv lved in parathyroid 
tumorigenesis, namely CDC73, MEN1, CASR and VDR, are not affected by inc eased 
methylation; therefore, m thylation i  not the major mole ular mechanism inducing t eir loss 
in parathyroid tumor cells; 
(5) Hype methylation ffects the p moter f genes encoding molecules of the Wnt/β-catenin 
pathway (Figure 1). Wnt/β-catenin is po tially deregulated in PCas by l ss of p rafibromin, 
which is a member of th  polymerase II c plex i teracting with β-catenin [36]. Therefore, 
Wnt/β-catenin deregulation has been suggested as a “hub” of parathyroid tumorigenesis [37] 
(Figure 1). Indeed, accumulatio  of atenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-catenin at the n clear level [38]. 
Table 1. Aberr nt gene expressions and related molecular mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Ge e Function Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1 1.2 
Tumor sup ressor involved in tra scriptional and 
ost-transcriptional control 
 70  
PRUNE2 9q21.2 
Tumor uppressor involved in the suppression of 
Ras homolog family member A activity 
 18% 
MEN1 11q 2 
Tumor suppres or associated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
thr ug  int ractio  with SIRT1 
 100  
APC 5q22.2 
Tumor suppressor, inhibitor of the  
Wnt/β-catenin p thway  33%–100% 
RASSF1A 3p21.31 Ras-association domai  family 1  100% 
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
Wnt/β-catenin pathway  100% 
SFRP2 4q3
Secreted frizzled related protein 2, inhibitor of the 
Wnt/β-catenin pathway 
SFRP4 7p14.1
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-cate in p thway  .a. 
A/ 6 .  li - t i  i i it   . . 
CDKN2B/p15 9p2 .  Cyclin-dependent kina e inhibit   . . 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19q13.42 microRNA cluster  58% 
Aberrantly expressed chromatin remodeling genes
HIST1H1C .  li ti - t i t  1.2  100  
I A  .  li ti - t i t  A  . . 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
Enhancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune ho olog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
miR-30b 8q24.22
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4  The pro oter r gions of the tumor suppressor g s known to be inv lved in p rathyroid 
tumorigen sis, namely CDC73, MEN1, CASR and VDR, are not ffected by inc ased 
methylatio ; therefore, methylation i  not the m jor mole ular mechanism inducing t eir loss 
in parathyroi  tumor ells; 
(5) Hype methylation ffects the pr moter f gen s ncoding molecules of t  Wnt/β-catenin 
pathway (Figure 1). Wnt/β-cateni  is potentially deregulated in PCas by l ss of p rafibromin, 
which is a member of th  polymerase II complex i teracting with β-catenin [36]. Therefore, 
Wnt/β-catenin der gulation has been suggested as  “hub” of parathyr id tumorigenesi  [37] 
(Figure 1). Indeed, accumulat on of β-catenin is controversial in PCas, with studies reporting 
constitutive accumulation of active unphosphorylated β-catenin [26] and others failing in the 
detection of total β-catenin at the n clear level [38]. 
Tab e 1. Aberrant gene exp ssi ns and related molecular mechanisms in parathyroid carcinomas 
compared with normal parathyroid glands. 
Gene ID Chr. 
Map 
Ge e Function Variation in 
PCas 
Frequency in 
PCas 
Loss of function mutated genes 
CDC73 1q31.2 
Tu or su pressor involved in tra scriptional and 
ost-transcriptio al control 
 70  
PRU E2 9 2 .2 
Tumor uppr sor involved in the suppression of 
Ras homolog family member A activity 
 18  
MEN1 11q12 
Tumor suppres or associated with  
MEN1 syndrome 
 13% 
Hypermethylated genes
HIC1 17p13 
Tumor suppressor involved in inhibition of E2F1 
thr ugh int ractio  with SIRT1 
 100% 
APC 5q22.2 
Tumor suppressor, inhibitor of the  
Wnt/β-catenin p thway  33%–100% 
RASSF1A 3p21.31 Ras-association domai  family 1 100% 
SFRP1 8p11.21 
Secreted frizzled related protein 1, inhibitor of the 
nt/β-catenin path ay 100% 
SFRP2 4q3
Secreted frizzled related protein 2, inhibitor of the 
nt/β-catenin path ay 
SFRP4 7p 4.1
Secreted frizzled related protein 4, inhibitor of the 
Wnt/β-catenin pathway  n.a. 
A/ 6 1.3 li - t i s  i i itor  n.a. 
CDKN2B/p15 9p2 .  Cyclin-dependent kina e inhibit   . . 
WT1 11p13 Wilms tumor 1, tumor suppressor  n.a. 
Hypomethylated genes 
C19MC 19 13.42 microRNA cluster  58  
Aberrantly expressed chromatin remodeling genes
HIST1H1C 6p22.2 Replication-dependent histone 1.2  100% 
I A  .  li ti - t i t  A  . . 
HIST1H2BB 6p22.2 Replication-dependent histone H2B  n.a. 
EZH2 7q36.1 
E hancer of zeste 2 polycomb repressive complex 
2 subunit 
 100% 
Chr., chromosome; PCas, parathyroid carcinomas; CDC73, cell division cycle 73; APC, Wnt signaling 
pathway regulator; PRUNE2, prune ho olog 2; MEN1, multiple endocrine neoplasia type 1 
syndrome; HIC1, hypermethylated in human cancers 1; SIRT1, sirtuin 1; C19MC, chromosome 19 
microRNA cluster; n.a., not available. 
n.a.
C1 MC, chromosome 19 microRNA cluster; GNAS, guani e nucleotide binding protein α stimulating complex
locus; n.a., not available.
6. Concl ding Remarks
Though e igenetic investigatio in PCas is limited a d needs further studies, available data
provide intriguing p rspectives and suggest new approaches in parathyroid tumorigenesis research;
the main remarks a :
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(1) Epigenetic studies increased the list of tumor suppressor genes lost in parathyroid cancers
(Table 1), suggesting that loss of tumor suppressor genes, rather than gain of oncogenes is a
hallmark of parathyroid tumorigenesis;
(2) Parafibromin, the most common tumor suppressor lost in PCas, emerges as a coordinator
regulating a number of different pathways: (1) Wnt/β-catenin; (2) chromatin remodeling;
(3) miRNA transcription (Figure 2);
(3) Most deregulated miRNAs in PCas are not exclusive of parathyroid cells, since they characterize
the miRNA signature of most common human cancers. As an example, the miR-222/221 cluster
is one of the most commonly upregulated miRNAs in human cancers. However, it is of interest
to consider that they belong to methylated loci and are common in the human embryonic stem
cell miRNA signature;
(4) Distant PCa metastases usually share the miRNA expression profile of the primitive tumors;
no data are available about their methylome signature.
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Figure 2. Effects of the loss of cell division cycle 73 (CDC73)/parafibromin on epigenetic regulatory 
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H1.2, H2A, H2B, SUV39H1, EZH2 and microRNAs biogenesis are represented; moreover, 
CDC73/parafibromin may modulate the Wnt/β-catenin pathway in PCas. H, histone; Pol II, RNA 
polymerase II; Ub, ubiquitination; K, lysine; RNF, ring finger protein; SUV39H1, suppressor of 
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dashed arrow, supposed, not demonstrated, effect; red thick arrow, increased or decreased 
expression levels; red cross, loss of expression. 
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polymerase II; Ub, ubiquitination; K, lysine; RNF, ring finger protein; SUV39H1, suppressor of
variegation 3–9 homolog 1; PRC2, polycomb repressive complex 2; EZH2, enhancer of zeste 2;
dashed arrow, supposed, not demonstrated, effect; red thick arrow, increased or decreased expression
levels; red cross, loss of expression.
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